Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | GNRHR | P30968 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 8/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845398 | 0.82 | GNRHR (0.40) | HTR2CGNRHRHTR2BHTR2ASIGMAR1 | |
| SCHEMBL22717381 | 0.78 | GNRHR (0.37) | HTR2CGNRHRHTR2BHTR2ASIGMAR1 | |
| SCHEMBL22845219 | 0.77 | HTR2C (0.39) | HTR2CGNRHRHTR2BHTR2ASIGMAR1 | |
| SCHEMBL22845489 | 0.72 | GNRHR (0.44) | GNRHRNPC1RAB9A | |
| SCHEMBL22845210 | 0.69 | ALDH1A1 (0.42) | HTR2CGNRHRHTR2AMCHR1CYP3A4 | |
| SCHEMBL22845205 | 0.69 | GNRHR (0.38) | HTR2CGNRHRSIGMAR1CYP3A4 | |
| SCHEMBL22845308 | 0.69 | DPP4 (0.52) | HTR2CHTR2BHTR2AHTR7 | |
| SCHEMBL22845486 | 0.69 | GNRHR (0.36) | HTR2CGNRHRSIGMAR1 | |
| SCHEMBL22845276 | 0.68 | REN (0.41) | NPC1RAB9A | |
| SCHEMBL24469835 | 0.68 | CRBN (0.39) | HTR2CMCHR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | HTR2C 467/4885GNRHR 2198/4885HTR2B 2013/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | HTR2C 467/4885GNRHR 2198/4885HTR2B 2013/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | HTR2C 467/4885GNRHR 2198/4885HTR2B 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.